A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Status:
Recruiting
Trial end date:
2029-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness of nipocalimab when compared to
placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell
volume falls below normal levels while the baby is developing in the womb) with live neonates
in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.